Patents Examined by Kevin Weddington
  • Pyridazine derivatives for inhibiting human stearoyl-CoA-desaturase
    Patent number: 7829712
    Abstract: Methods of treating an SCD-mediated disease or condition in a mammal, preferably a human, are disclosed, wherein the methods comprise administering to a mammal in need thereof a compound of formula (I) where x, y, G, J, K, L, M, Q, W, V, R2, R3, R5, R5a, R6, R6a, R7, R7a, R8 and R8a are defined herein. Pharmaceutical compositions comprising the compounds of formula (I) are also disclosed.
    Type: Grant
    Filed: September 20, 2005
    Date of Patent: November 9, 2010
    Assignee: Xenon Pharmaceuticals Inc.
    Inventors: Rajender Kamboj, Zaihui Zhang, Jianmin Fu, Serguei Sviridov, Sultan Chowdhury, Vishnumurthy Kodumuru
  • Adenosine receptor selective modulators
    Patent number: 7825255
    Abstract: The invention relates to the compounds of formula (I), to a method for producing the same and to the use thereof as medicaments.
    Type: Grant
    Filed: February 28, 2002
    Date of Patent: November 2, 2010
    Assignee: Bayer Schering Pharma Aktiengesellschaft
    Inventors: Ulrich Rosentreter, Thomas Krämer, Andrea Vaupel, Walter Hübsch, Nicole Diedrichs, Thomas Krahn, Klaus Dembowsky, Johannes-Peter Stásch
  • Cosmetic or dermatological formulations of improved pearlescence
    Patent number: 7820150
    Abstract: A cosmetic or dermatological preparation which comprises a C12-C40 fatty acid, a C12-C40 fatty alcohol, an amphiphilic polymer, an associative polymer and/or a siloxane elastomer, sodium and/or potassium hydroxide, and a pigment and/or a dye.
    Type: Grant
    Filed: January 20, 2004
    Date of Patent: October 26, 2010
    Assignee: Beiersdorf AG
    Inventors: Silke Kohlhase, Andreas Bleckmann, Heidi Riedel, Stefanie Von Thaden
  • Pharmaceutical composition comprising N-aryl N? morpholino/piperidino thiocarbamide derivatives for treating type II diabetes
    Patent number: 7820656
    Abstract: Disclosed is a medicament comprising N-aryl N? morpholino/piperidino thiocarbamide derivatives represented by the following formula 1 for preventing and treating diabetes, diabetic complications, insulin resistance and insulin resistance syndrome, and can be used in drugs, foods, and beverages inducing an effect of preventing and treating diabetes, diabetic complications, insulin resistance and insulin resistance syndrome of modern people who suffer from the increasing development of diabetes resulting from environmental factors, such as intake of westernized foods, obesity, and so on: wherein, X is O or C, and R represents 4-chlorophenyl, 2-methylphenyl, 3-methoxypheny, 3-methylphenyl, or phenyl group.
    Type: Grant
    Filed: December 22, 2005
    Date of Patent: October 26, 2010
    Inventor: Sung-Jin Kim
  • Method of treating neutrophil-related diseases with topical anesthetics
    Patent number: 7816374
    Abstract: A therapeutic method is provided to treat neutrophil-associated pulmonary diseases, such as chronic obstructive pulmonary disease, by locally administering to a mammal in need of such treatment, an effective amount of a topical anesthetic, such as lidocaine, or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: May 8, 2008
    Date of Patent: October 19, 2010
    Assignee: Mayo Foundation for Medical Education and Research
    Inventors: Gerald J. Gleich, Loren W. Hunt, Jr.
  • Orally distintegrating formulation and process for preparing the same
    Patent number: 7815935
    Abstract: An orally disintegrating formulation and its preparation are provided. The orally disintegrating formulation comprises an effective amount of a pharmaceutically active ingredient and a matrix, wherein the matrix contains an amino acid and pullulan. The orally disintegrating formulation can disintegrate rapidly in oral cavity and be taken without aid of water; Moreover, the formulation has a low hygroscopicity, so that the requirements for storing or producing the formulation is decreased, and the storage life is elongated to facilitate the administration by a patient and the preparation of the protein and vaccine drugs.
    Type: Grant
    Filed: April 30, 2005
    Date of Patent: October 19, 2010
    Assignee: Quantum Hi-Tech (Beijing) Research Institute
    Inventors: Hewei Li, Hongfei Wang, Mingzhou Wang, Linyuan Wang
  • Therapeutic agents for diabetes
    Patent number: 7807663
    Abstract: A pharmaceutical composition for preventing and/or treating diabetes, diabetic complication, hyperinsulinemia, disorders of glucose metabolism or obesity, comprising a combination of the following compound, analogues or pharmaceutically acceptable salts thereof with a hypoglycemic agent.
    Type: Grant
    Filed: August 8, 2005
    Date of Patent: October 5, 2010
    Assignee: Ajinomoto Co., Inc.
    Inventors: Takao Ikenoue, Yoko Kageyama, Yukio Iino, Nobuo Kondo
  • Utilization of dialkylfumarates
    Patent number: 7803840
    Abstract: The present invention relates to the use of certain dialkyl fumarates for the preparation of pharmaceutical preparations for use in transplantation medicine or for the therapy of autoimmune diseases and said compositions in the form of micro-tablets or pellets. For this purpose, the dialkyl fumarates may also be used in combination with conventional preparations used in transplantation medicine and immunosuppressive agents, especially cyclosporines.
    Type: Grant
    Filed: March 17, 2009
    Date of Patent: September 28, 2010
    Assignee: Biogen Idec International GmbH
    Inventors: Rajendra Kumar Joshi, Hans-Peter Strebel
  • Methods and reagents for the treatment of metabolic disorders
    Patent number: 7795310
    Abstract: The invention features compositions, methods, and kits for the treatment of metabolic disorders such as diabetes and obesity.
    Type: Grant
    Filed: June 30, 2005
    Date of Patent: September 14, 2010
    Assignee: CombinatoRx, Inc.
    Inventors: Margaret S. Lee, Grant R. Zimmermann, Alyce L. Finelli, Daniel Grau, Curtis Keith, M. James Nichols
  • Histone deacetylase inhibitor enhancement of trail-induced apoptosis
    Patent number: 7786170
    Abstract: Due to the poor long-term clinical outcome in the adult patients with several forms of acute leukemia novel treatment strategies are needed to overcome resistance and sensitize the leukemia blasts to the extrinsic and intrinsic pathway of apoptosis. Treatment with LAQ824 and Apo-2L/TRAIL alone has been recognized to induce apoptosis of leukemia blasts but intrinsic mechanisms of resistance limit the antileukemia activity of either agent when administered alone. The inventive method overcomes the resistance to current apoptosis inducing treatments demonstrated by AML and CML-BC cells by concomitantly administering Apo-2L/TRAIL with the histone deacetylase inhibitor LAQ824.
    Type: Grant
    Filed: June 6, 2005
    Date of Patent: August 31, 2010
    Assignee: University of South Florida
    Inventor: Kapil N. Bhalla
  • Pharmaceutical formulations of antineoplastic agents
    Patent number: 7786118
    Abstract: In its several embodiments, this invention discloses a pharmaceutical formulation comprising at least one antineoplastic agent or a pharmaceutically acceptable salt thereof, and at least one dissolution enhancing agent sufficient to substantially dissolve said at least one antineoplastic agent in at least one aqueous diluent, wherein said dissolution enhancing agent is urea, L-histidine, L-threonine, L-asparagine, L-serine, L-glutamine or mixtures thereof; a lyophilized powder comprising said pharmaceutical formulation, and articles of manufacture thereof.
    Type: Grant
    Filed: March 12, 2009
    Date of Patent: August 31, 2010
    Assignee: Schering Corporation
    Inventors: Sydney Ugwu, Vinay Radhakrishnan, Peter M. Ihnat, Leonore C. Witchey-Lakshmanan
  • Methods for modulating Lyn kinase activity and treating related disorders
    Patent number: 7776870
    Abstract: The present invention relates to compounds and pharmaceutically acceptable salts thereof and formulations comprising the compounds or a pharmaceutically acceptable salts thereof that are useful in modulating lyn kinase activity. In particular, the compounds or a pharmaceutically acceptable salts thereof are useful for treating or preventing a disease or disorder including cardiovascular disease, dyslipidemia, dyslipoproteinemia, a disorder of glucose metabolism, metabolic syndrome (i.e., Syndrome X), a peroxisome proliferator activated receptor-associated disorder, septicemia, a thrombotic disorder, type II diabetes, obesity, pancreatitis, hypertension, renal disease, inflammation, or impotence.
    Type: Grant
    Filed: August 22, 2006
    Date of Patent: August 17, 2010
    Assignee: Melior Pharmaceuticals I, Inc.
    Inventors: Andrew Reaume, Michael S. Saporito
  • Heterocyclic derivatives and their use as therapeutic agents
    Patent number: 7777036
    Abstract: Methods of treating an SCD-mediated disease or condition in a mammal, preferably a human, are disclosed, wherein the methods comprise administering to a mammal in need thereof a compound of formula (I) where y, G, K, L, M, W, V, R2, R3, R4a, R6, R6a, R7, R7a, R8 and R8a are defined herein. Pharmaceutical compositions comprising the compounds of formula (I) are also disclosed.
    Type: Grant
    Filed: September 20, 2005
    Date of Patent: August 17, 2010
    Assignee: Xenon Pharmaceuticals Inc.
    Inventors: Rajender Kamboj, Zaihui Zhang, Jianmin Fu, Mehran Seid Bagherzadeh, Serguei Sviridov, Sultan Chowdhury, Shifeng Liu, Vishnumurthy Kodumuru
  • Use of PDE4 inhibitors for the treatment of diabetes mellitus
    Patent number: 7776893
    Abstract: The invention relates to the use of certain known PIDE4 inhibitors for the treatment of diabetes mellitus and accompanying disorders thereof.
    Type: Grant
    Filed: September 2, 2004
    Date of Patent: August 17, 2010
    Assignee: NYCOMED GmbH
    Inventor: Hans-Peter Kley
  • Method for enhancing glucose uptake into warm-blooded animal adipocytes
    Patent number: 7772272
    Abstract: The present invention provides a pharmaceutical composition for enhancement of glucose uptake into warm-blooded animal cells, treatment of diabetes, treatment or prevention of diabetes complications etc., treatment or prevention of diabetes or diabetes complications caused by insulin resistance syndrome, and the like, comprising as an active ingredient an HMG-CoA reductase inhibitor.
    Type: Grant
    Filed: April 27, 2004
    Date of Patent: August 10, 2010
    Assignee: Daiichi Sankyo Company, Limited
    Inventors: Toshiyuki Takagi, Iichiro Shimomura
  • Antifolate combination therapies
    Patent number: 7772209
    Abstract: A method of administering an antifolate to a mammal in need thereof, comprising administering an effective amount of said antifolate in combination with a methylmalonic acid lowering agent.
    Type: Grant
    Filed: July 11, 2007
    Date of Patent: August 10, 2010
    Assignee: Eli Lilly and Company
    Inventor: Clet Niyikiza
  • Pharmaceutical compositions comprising CBx cannabinoid receptor modulators and potassium channel modulators
    Patent number: 7763607
    Abstract: Described herein are pharmaceutical compositions comprising therapeutically effective quantities of (i) a KATP channel modulator; and (ii) a CBx modulator. Also described herein are methods of making and using these compositions.
    Type: Grant
    Filed: April 26, 2007
    Date of Patent: July 27, 2010
    Assignee: Solvay Pharmaceuticals GmbH
    Inventors: Jochen Antel, Peter-Colin Gregory, Josephus Hubertus Maria Lange, Michael Firnges, Dania Reiche
  • Methods for modulating metabolism
    Patent number: 7759398
    Abstract: The subject invention provides materials and methods for modulating a variety of biological factors to treat biological conditions associated with the factors. In one embodiment of the invention, a cysteamine compound is administered to a patient to treat hypercholesterolemia and/or complications associated with hypercholesterolemia. In another embodiment, a cysteamine compound is administered to a patient to prevent the onset of diabetes in an at-risk patient and/or treat or prevent the onset of diabetes-associated complications.
    Type: Grant
    Filed: April 29, 2005
    Date of Patent: July 20, 2010
    Assignee: Omega Bio-Pharma (I.P.3) Limited
    Inventors: Bill Piu Chan, Gary Kwan Po Wong, Jinxian Xu, Francis Chi
  • Use of lecithin as a medication for the treatment of psoriasis
    Patent number: 7759325
    Abstract: Methods and compositions for the prevention and treatment of recent and old dermatitis, especially psoriasis, using lecithin or a lecithin-rich extract. According to one embodiment, phospholipids constituting the lecithin are esterified by Omega 3-type polyunsaturated fatty acids, in particular by docosahexaensic acid (DHA) and eicosapentaenoic acid (EPA) or by an alkyl glycerol. The lecithin can be of marine origin, extracted from a marine organisms such as fish, shrimp, krill, zooplankton, algae, and phytoplankton, which are advantageous in that their phospholipids, especially phosphatidylcholine, are naturally esterified by Omega 3 fatty acids, and essentially by DHA and EPA.
    Type: Grant
    Filed: April 11, 2006
    Date of Patent: July 20, 2010
    Assignee: SC Dicophar
    Inventor: Paul Dupont
  • Soluble forms of amoxicillin and treatment of animals
    Patent number: 7759334
    Abstract: A solid mixture or aqueous solution of amoxicillin antibacterial agent with a material that aids in its dissolution in water to render it ingestive and palatable.
    Type: Grant
    Filed: June 27, 2007
    Date of Patent: July 20, 2010
    Assignee: Pharmaceutical Solutions, Inc.
    Inventors: Michael A. Strobel, Pat Soderlund, Jr.